Rayvow Eli Lilly Nederland B.V. · Authorised · authorised 17 Aug 2022 · ATC N02CC08
Therapeutic indication (EMA)
RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
Active substance
Lasmiditan
- SFDA 6
- US FDA 1
- EMA 1
- US price lines 2
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Acumig | 50 mg | Film-coated tablet · Oral use | 4 Blister | SAR 80.45 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Acumig | 100 mg | Film-coated tablet · Oral use | 8 Blister | SAR 321.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Acumig | 50 mg | Film-coated tablet · Oral use | 8 Blister | SAR 160.95 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Acumig | 100 mg | Film-coated tablet · Oral use | 4 Blister | SAR 160.95 | Generic · Prescription | Jazz Pharmaceutical Ireland Ltd | Valid |
| REYVOW | 50 mg | Film-coated tablet · Oral use | 8 Blister | SAR 172.40 | NCE · Prescription | Eli Lilly and Company | Valid |
| REYVOW | 100 mg | Film-coated tablet · Oral use | 8 Blister | SAR 344.90 | NCE · Prescription | Eli Lilly and Company | Valid |
Indications — CHI Daman Drug Formulary
MIGRAINE/ HEADACHE
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| REYVOW | EQ 50MG BASE; EQ 100MG BASE; EQ 200MG BASE | tablet · oral | ELI LILLY AND CO | Discontinued | 11 Oct 2019 |
EMA European Union — centrally authorised medicines
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | REYVOW 100 MG TABLET | $88.77148 | per EA | 20 May 2026 |
| US NADAC | REYVOW 50 MG TABLET | $88.69728 | per EA | 20 May 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 15 Sep 2022 REYVOW — safety-related labeling change
Labeling sections changed: Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.